Objective: To establish a database of CD36 antigen-negative donors through large-scale screening of apheresis platelet donors in Shenzhen for CD36 deficiency subtypes and blood group distribution, and to assess clinical demand and blood supply capacity through a retrospective analysis of the apheresis platelet donation volumes from 2019 to 2023. Methods: Flow cytometry with fluorescent CD36 monoclonal antibodies was employed to screen platelet/monocyte CD36 deficiency (Type I and Ⅱ), and statistical analyses were conducted using SPSS software (version 27.0). Results: Among 11 603 apheresis platelet donors, 248 (2.14%) exhibited CD36 deficiency, comprising 51 type Ⅰ (0.43%, 51/11, 603) and 197 type Ⅱ (1.70%, 197/11, 603) cases, with significant difference (P<0.001). CD36 deficient platelets were mainly distributed in blood group B (2.28%, 902.3/39 602.1) and AB (2.14, 269/12 544.5), significantly exceeding those in blood group A (1.43%, 667/46 508.4) and O (1.64%, 1 000/60 965.6) (P<0.001). The proportion of donors with 10-100 U from CD36 deficient donors was the highest (51%, 1 446.4/2 838.3). Conclusion: Sustained screening for CD36-deficient donors is recommended to meet the clinical transfusion needs for immunized patients and those requiring antigen-negative products. Regional resource-sharing mechanisms should be optimized to maximize utilization of CD36-deficient platelet inventories.

Panic disorder has the characteristics of early onset, late detection, high comorbidity rate and low treatment rate, which have a lasting impact on the physical and mental health of children and adolescents. Early intervention can reduce the risk of various mental disorders in adulthood. Cognitive-behavioral therapy(CBT), as a routine social psychological treatment, is also recommended as a first-line intervention for the treatment of panic disorder in children and adolescents. However, due to diagnostic and application difficulties, CBT has not received sufficient attention in the field of panic disorder in children and adolescents. Through a systematic review of the application of CBT in children and adolescents with panic disorder, it found that panic control therapy(PCT)and intensified CBT(iCBT) therapy are the main methods for treating panic disorder in children and adolescents, both of which can effectively alleviate the symptoms of panic disorder in children and adolescents.Cognitive restructuring, exposure, respiratory training and parental involvement are effective components of CBT treatment for panic disorder.In the future, it is necessary to increase attention to underage panic disorder, improve CBT cultural adaptation, use diverse treatment methods, objectively evaluate standards, and optimize research design, to promote the improvement of treatment effectiveness and the development of clinical research.

Panic disorder has the characteristics of early onset, late detection, high comorbidity rate and low treatment rate, which have a lasting impact on the physical and mental health of children and adolescents. Early intervention can reduce the risk of various mental disorders in adulthood. Cognitive-behavioral therapy(CBT), as a routine social psychological treatment, is also recommended as a first-line intervention for the treatment of panic disorder in children and adolescents. However, due to diagnostic and application difficulties, CBT has not received sufficient attention in the field of panic disorder in children and adolescents. Through a systematic review of the application of CBT in children and adolescents with panic disorder, it found that panic control therapy(PCT)and intensified CBT(iCBT) therapy are the main methods for treating panic disorder in children and adolescents, both of which can effectively alleviate the symptoms of panic disorder in children and adolescents.Cognitive restructuring, exposure, respiratory training and parental involvement are effective components of CBT treatment for panic disorder.In the future, it is necessary to increase attention to underage panic disorder, improve CBT cultural adaptation, use diverse treatment methods, objectively evaluate standards, and optimize research design, to promote the improvement of treatment effectiveness and the development of clinical research.

Depressive disorder is one of the common mental disorders, and its occurrence is usually attributed to the combined effects of multiple factors.The single genetic factor can't fully explain the cause of depressive disorder.Family factors have an important impact on the occurrence of depressive disorder, however, the impact of family factors on depressive disorder and its treatment has not been paid enough attention to.This paper reviewed the recent researches on family factors affecting depressive disorder and family therapy for depressive disorder.The results showed that family factors had an impact on depression patients of any age, and adverse family factors were risk factors for the occurrence, sustainable development and recurrence of depressive disorder.Most of the previous studies were horizontal, but few were longitudinal research.Family therapy plays a positive role in the treatment of depressive disorder and has a significant effect on the acute phase of depression except for major depressive disorder (MDD). Family therapy can quickly relieve the symptoms of depression.Further studies on family-based treatment intervention strategies for MDD are needed in the future, and more longitudinal studies are needed to further analysis of the influence of family factors on depressive disorder.

OBJECTIVE： To evaluate the efficacy and safety of icotinib in the treatment of advanced non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use. METHODS： Retrieved from the Cochrane library， PubMed， Sciencedirect， CNKI， Wanfang database and VIP， RCTs about icotinib or icotinib combined with routine treatment or with other drugs （trial group） versus routine treatment or other drugs （control group） in the treatment of advanced NSCLC were collected. After literature screening， data extraction and literature quality evaluation with Cochrane collaboration bias risk assessment tool 5.1.0， Meta-analysis was performed by using Rev man 5.3 statistical software. RESULTS： A total of 27 RCTs were included， involving 2 345 patients. Results of Meta-analysis showed that response rate [OR＝1.64， 95％CI（1.36， 1.97）， P＜0.000 01] and disease control rate [OR＝1.68， 95％CI（1.39， 2.04）， P＜0.000 01] in trial group were significantly higher than control group； the incidence of ADR in trial group [OR＝0.59， 95％CI（0.48， 0.72）， P＜0.000 01] was significantly lower than control group. CONCLUSIONS： Icotinib shows good efficacy and safety in the treatment of advanced NSCLC.

The E (envelope) protein is the smallest structural protein in all coronaviruses and is the only viral structural protein in which no variation has been detected. We conducted genome sequencing and phylogenetic analyses of SARS-CoV. Based on genome sequencing, we predicted the E protein is a transmembrane (TM) protein characterized by a TM region with strong hydrophobicity and alpha-helix conformation. We identified a segment (NH2-_L-Cys-A-Y-Cys-Cys-N_-COOH) in the carboxyl-terminal region of the E protein that appears to form three disulfide bonds with another segment of corresponding cysteines in the carboxyl-terminus of the S (spike) protein. These bonds point to a possible structural association between the E and S proteins. Our phylogenetic analyses of the E protein sequences in all published coronaviruses place SARS-CoV in an independent group in Coronaviridae and suggest a non-human animal origin.
Amino Acid Sequence ; Base Sequence ; Cluster Analysis ; Codon ; genetics ; Gene Components ; Genome, Viral ; Membrane Glycoproteins ; metabolism ; Membrane Proteins ; genetics ; metabolism ; Molecular Sequence Data ; Phylogeny ; Protein Conformation ; SARS Virus ; genetics ; Sequence Alignment ; Sequence Analysis, DNA ; Sequence Homology ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins ; genetics ; metabolism